Ten stocks close to their 52-week high
Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

DSIJ Intelligence Article rating: 4.1

The market opened in the green on June 22, 2020. The previous trading session witnessed the Sensex going up 523.68 points to end at 34,731.73 and the Nifty was up 152.75 points to close at 10,244.40 .

Stocks close to their 52-week low
Stocks close to their 52-week low

Stocks close to their 52-week low

DSIJ Intelligence Article rating: 3.3

The market opened in the green on June 22, 2020. The previous trading session witnessed the Sensex going up 523.68 points to end at 34,731.73 and the Nifty was up 152.75 points to close at 10,244.40 .

Five stocks with buying interest
Five stocks with buying interest

Five stocks with buying interest

DSIJ Intelligence Article rating: 3.5

The market opened in the green on June 22, 2020, overall volumes in futures & options currently stand at 1.90 crore contracts with a turnover of Rs. 11,06,171.96 crore.
 

Five stocks with selling interest
Five stocks with selling interest

Five stocks with selling interest

DSIJ Intelligence Article rating: 4.0

The market opened in the green on June 22, 2020, overall volumes in futures & options currently stand at 1.90 crore contracts with a turnover of Rs. 11,06,171.96 crore.

Glenmark stock jumps 29.99 per cent on launching COVID-19 drug
Glenmark stock jumps 29.99 per cent on launching COVID-19 drug

Glenmark stock jumps 29.99 per cent on launching COVID-19 drug

DSIJ Intelligence Article rating: 3.0

Glenmark has received permission from Indian drug regulator to manufacture and market Favipiravir introduced as ‘Fabiflu’, the first oral anti-viral treatment option for mild to moderate COVID-19 patients in India.

Cipla launches Remdesivir under its brand name CIPREMI
Cipla launches Remdesivir under its brand name CIPREMI

Cipla launches Remdesivir under its brand name CIPREMI

DSIJ Intelligence Article rating: 3.8

Cipla Limited today announced the launch of Remdesivir under its brand name CIPREMI. United States Food and Drug Administration (USFDA) issued an emergency use authorisation (EUA) to Gilead Sciences Inc. for emergency use of the drug for the treatment of COVID-19 patients.

Alembic Pharma attains new lifetime high
Alembic Pharma attains new lifetime high

Alembic Pharma attains new lifetime high

Nidhi Jani Article rating: 5.0

Including the latest ANDA approval, the company has a total of 124 ANDA approvals, of which, 110 are at the final stage and 14 have been granted tentative approvals by United States Food and Drug Administration (USFDA).

Biocon Pharma collaborates with DKSH
Biocon Pharma collaborates with DKSH

Biocon Pharma collaborates with DKSH

DSIJ Intelligence Article rating: 3.8

Biocon Ltd today announced that Biocon’s subsidiary, Biocon Pharma Limited and DKSH Business Unit Healthcare, have signed an agreement under which DKSH will sell and distribute seven of Biocon Pharma’s generic formulations in Singapore and Thailand.

L&T arm signs MoU with American firm KBR
L&T arm signs MoU with American firm KBR

L&T arm signs MoU with American firm KBR

Nidhi Jani Article rating: 4.0

Under this MoU, both the companies will develop business opportunities. L&T Hydrocarbon Engineering will completely bid for the technologies of KBR with special focus on India, South East Asia, Africa and Middle East.

A lazy start for the market
A lazy start for the market

A lazy start for the market

DSIJ Intelligence-3 Article rating: 5.0

Bulls were on the top of the world and they had a rocking party in the last two trading sessions of the last week. But, as we enter the fresh week, the Indian markets may get a reality check and they may halt their big party.

RSS
First29522953295429552957295929602961Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR